Research funder · United States
Alzheimer's Drug Discovery Foundation
Nonprofit organization
- Grants since 2016
- 326
- Awarded, last 5 years (where amounts are published)
- $245.1M
- Funded works, last 5 years
- 1 178
- Funded works, all time
- 2 272
Grants
2022–2024 · research · Diagnostics Accelerator
Clinical Implementation of Blood-Based Biomarkers for Alzheimer’s Disease: Clinical Validation, IVD Product Development, and Market Development
David Wilson · Quanterix (United States)
2022–2026 · research · Drug Discovery
Discovery of selective LRP1 inhibitors to prevent tau uptake and spread
Kenneth Kosik · University of California, Santa Barbara
2022–2025 · research · Clinical
Long Acting GM-CSF Fusion Protein (PDM608) for the Treatment of Alzheimer’s Disease
Sean Joseph · Scripps Research Institute
2022–2024 · research · Biomarkers
Validation of a Novel Magnetic Resonance Imaging (MRI) Technology for both Diagnostic Screening and Quantification of Brain Vascular Physiology in Alzheimer's-Disease-Related Dementias
Codi Gharagouzloo · Imaginostics Inc
2022–2028 · research · Clinical
2-Hydroxybenzylamine (2-HOBA) Proof-of Concept, Dose-Finding, Biomarker Study in Early Alzheimer’s Patients
John Rathmacher · Mti Biotech Inc.
2022–2025 · research · Clinical
Evaluating the effects of GLP-1 analog, oral semaglutide, as a treatment for sporadic behavioral variant frontotemporal dementia (bvFTD)
Paul Edison · Imperial College London
2022–2024 · research · Diagnostics Accelerator
Validation of the Retinal Deep Phenotyping(TM) platform for the detection of the likely cerebral amyloid status to aid in the diagnosis of Alzheimer’s disease
Jean-Philippe Sylvestre · Optina Diagnostics (Canada)
2022 · research · Diagnostics Accelerator
Diagnostics Accelerator Speech & Language Consortium: Harmonized Repository for the Exploration of Speech and Language Biomarkers for Neurodegenerative Disease
David Bates · Linus Health, Inc.
2022–2025 · prize · Prevention
2021 Annual Goodes Prize for Excellence in Alzheimer’s Drug Discovery to support parts of the ground-breaking MET-FINGER clinical trial and other WW-FINGERS related research and dissemination activities
Miia Kivipelto · Fingers Brain Health Institute
2022–2024 · research · Diagnostics Accelerator
Development of cell free messenger RNA-based non-invasive diagnostic biomarker for Alzheimer's disease
John Sninsky · Superfluid Dx
2022–2024 · research · Diagnostics Accelerator
Identifying a Patient-Specified Core Digital Measures Set in Alzheimer’s Disease and Related Dementias
Pip Griffiths · Digital Medicine Society (dime)
2022–2025 · research · Drug Discovery
Leveraging exercise to improve cognitive function in Alzheimer’s Disease
Christiane Wrann · Massachusetts General Hospital (p)
2022–2027 · research · Prevention
MET-FINGER-APOE: A randomized controlled trial of multimodal lifestyle intervention and metformin to prevent cognitive impairment and disability in a cognitively healthy APOE4 enriched at-risk population
Miia Kivipelto · Imperial College London
2022–2026 · research · Biomarkers
The development and evaluation of a clinical RT-QuIC test for diagnosis of TDP-43 linked Fronto-temporal dementias
Neil Mckenzie · University of Edinburgh
2022–2026 · research · Biomarkers
Measurement of immune cell recruitment as a biomarker of neuroinflammation in Alzheimer's disease and other diseases of the central nervous system
Peter Snyder · Mindimmune Therapeutics, Inc.
2022–2025 · research · Diagnostics Accelerator
Plasma neuroinflammatory biomarkers for the diagnosis of dementia subtypes
Matthew Pase · Monash University
2021–2022 · research · Diagnostics Accelerator
Blood-based immune biomarkers for Alzheimer's disease diagnosis and its early detection
Thomas Montine · Board Of Trustees Of The Leland Stanford Junior University
2021–2022 · research · Diagnostics Accelerator
Validation of blood based biomarkers for the detection of brain amyloid accumulation before clinical onset of dementia.
Blaine Roberts · Neurovision Imaging, Inc.
2021–2024 · research · Drug Discovery
Effects of Chaperone-Mediated Autophagy in Alzheimer's Disease
Sharon Rosenzweig-Lipson · Life Biosciences
2021–2027 · research · Clinical
A Placebo Controlled, Randomized Double-blind Parallel Group 12-month Trial of Fasudil for the Treatment of Mild Cognitive Impairment Due to Alzheimer’s Disease, Nested within a Multi-Arm Phase 2 Clinical Trial Platform
Clive Ballard · University of Exeter
2021–2023 · research · Diagnostics Accelerator
Easy and early plasma pTau181 detection with the LUMIPULSE G platform as indicator of Alzheimer's disease.
Manu Vandijck · Fujirebio Europe Nv
2021–2023 · research · Diagnostics Accelerator
Fixational eye motion as biomarker for mild cognitive impairment
Christy Sheehy · C. Light Technologies, Inc.
2021–2024 · research · Diagnostics Accelerator
Digital Multimodal Neuropsychological Phenotyping for the Detection of Cognitive Decline in Aging Adults
Russell Banks · Neurotrack Technologies (United States)
2021–2027 · research · Diagnostics Accelerator
Alzheimer’s Disease Digital Biomarker Discovery: Framingham Cognitive Aging and Dementia Study
Rhoda Au · Boston University
2021–2025 · research · Diagnostics Accelerator
Neurofilament (Nf) as a Fluid Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (f-FTD)
Sri Pullagura · Foundation For The National Institutes Of Health, Inc.
2021–2025 · research · Clinical
MIB-626 FOR TREATMENT OF MILD DEMENTIA PATIENTS
David Livingston · Metro International Biotech
2021–2026 · research · Clinical
Non-Invasive Brain Stimulation for Gamma Induction and Cognitive Enhancement in FTD
Emiliano Santarnecchi · Massachusetts General Hospital (p)
2021–2026 · research · Clinical
Open-label Clinical Trial of Nabilone for Neuropsychiatric Symptoms in Frontotemporal Dementia
Simon Ducharme · McGill University
2021–2027 · research · Clinical
Testing low-dose efavirenz treatment for Alzheimer’s disease: a phase 1b dosing, target-engagement and exploratory biomarker study.
E.G.B. (Jort) Vijverberg · Amsterdam Umc Research Bv
2021–2022 · research · Diagnostics Accelerator
Development of a Biosample Database to Investigate Beta-Amyloid (Aß), Phospho-Tau (P-tau), and Neurofilament Light Chain (NfL) Blood-Based and Digital Biomarkers in Older Volunteers Screened for Preclinical Alzheimer’s Disease (AD), Prodromal AD, or Mild AD.
Doug Beauregard · Gap Innovations, Pbc
2021–2024 · research · Drug Discovery
Development of a <i>PIKFYVE</i> antisense oligonucleotide (ASO) treatment for FTD
Wen-Hsuan Chang · Acurastem Incorporated
2021–2024 · research · Diagnostics Accelerator
Digitally-enhanced personalized medicine: accurate selection of subjective cognitive decline and measuring progression of mild cognitive impairment
Ioannis Tarnanas · Altoida, Inc.
2021–2026 · research · Clinical
Phase II Clinical Trial to Evaluate the Safety and Feasibily of Senolytic Therapy in Alzheimer's Disease
Miranda Orr · Washington University in St. Louis
2021–2023 · research · Biomarkers
Molecular neuroimaging of RIPK1/necroptosis in Alzheimer's disease
Martin Zhang · Massachusetts General Hospital (p)
2021–2025 · research · Diagnostics Accelerator
PROSPECT-AD: Population-based scReening Over SPEech for Clinical Trials in AD
Nicklas Linz · Ki Elements
2021–2022 · research · Biomarkers
Misfolded Alpha-Synuclein Aggregates in CSF as Diagnostic & Prognostic Markers for Dementia
Russell Lebovitz · Amprion (United States)
2021–2024 · research · Diagnostics Accelerator
Integration of multiple digital technologies for the early detection of neurodegenerative diseases
Zoe Kourtzi · Alzheimer’s Research UK
2021–2026 · research · Biomarkers
Pre-competitive Analytical Validation of SV2A PET as a Biomarker of Synaptic Density Project
Sri Pullagura · Foundation For The National Institutes Of Health, Inc.
2021–2025 · research · Prevention
Can Lifestyle Changes Stop or Reverse the Progression of MCI Due to Early-Stage Alzheimer's Disease?
Dean Ornish · Preventive Medicine Research Institute
2021–2024 · research · Drug Discovery
Restoration of healthy Wnt signalling in the neurovascular unit through inhibition of Notum carboxylesterase activity: a Lead to Preclinical Candidate Program for Alzheimer’s disease.
Fiona Ducotterd · University College London